798 results match your criteria heart failure-associated


[The acute and long-term outcome of patients with ST segment elevation myocardial infarction concurrent with chronic total occlusion].

Zhonghua Xin Xue Guan Bing Za Zhi 2021 Jun;49(6):586-592

Coronary Heart Disease Center, National Center for Cardiovascular Diseases and Fuwai Hospital, China Academy of Medical Science and Peking Union Medical College, Beijing 100037, China.

To evaluate the acute and long-term outcome of patients with ST segment elevation myocardial infarction (STEMI) concurrent with chronic total occlusion (CTO) undergoing primary percutaneous coronary intervention (PCI). 11 905 STEMI patients from the China Acute Myocardial Infarction Registry were enrolled in this study and divided into CTO group and non-CTO group according to the angiography results of primary PCI. 1∶3 propensity score matching was used to match the patients between the two groups. Read More

View Article and Full-Text PDF

A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.

Int J Chron Obstruct Pulmon Dis 2021 31;16:1461-1475. Epub 2021 May 31.

RTI Health Solutions, Barcelona, Spain.

Background: The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A Post-Authorisation Safety Study (PASS) was initiated to assess potential cardiovascular safety concerns for aclidinium.

Objective: To estimate the adjusted incidence rate ratio (IRR) for hospitalisation for heart failure in patients with COPD who were new users of aclidinium, tiotropium, other LAMA, long-acting beta-agonists/inhaled corticosteroids (LABA/ICS), and LAMA/LABA were compared with initiators of LABA. Read More

View Article and Full-Text PDF

PGC-1α deficiency reveals sex-specific links between cardiac energy metabolism and EC-coupling during development of heart failure in mice.

Cardiovasc Res 2021 Jun 4. Epub 2021 Jun 4.

A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.

Aims: Biological sex has fundamental effects on mammalian heart physiology and pathogenesis. While it has been established that female sex is a protective factor against most cardiovascular diseases (CVDs), this beneficial effect may involve pathways associated with cardiac energy metabolism. Our aim was to elucidate the role of transcriptional coactivator PGC-1α in sex dimorphism of heart failure development. Read More

View Article and Full-Text PDF

The Case for Cadmium and Lead Heavy Metal Screening.

Am J Med Sci 2021 May 25. Epub 2021 May 25.

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY, USA.

Exposure to cadmium and lead is widespread, and is related to environmental contamination, occupational sources, food, tobacco and other consumer products. Lower socioeconomic status increases the risk of heavy metal exposure and the diseases associated with cadmium and lead toxicity. Concurrent toxicity with both cadmium and lead is likely but has not often been assessed. Read More

View Article and Full-Text PDF

Cardiac Energy Metabolism in Heart Failure.

Circ Res 2021 May 13;128(10):1487-1513. Epub 2021 May 13.

Division of Endocrinology and Metabolism, University of Iowa Carver College of Medicine, Iowa City (E.D.A.).

Alterations in cardiac energy metabolism contribute to the severity of heart failure. However, the energy metabolic changes that occur in heart failure are complex and are dependent not only on the severity and type of heart failure present but also on the co-existence of common comorbidities such as obesity and type 2 diabetes. The failing heart faces an energy deficit, primarily because of a decrease in mitochondrial oxidative capacity. Read More

View Article and Full-Text PDF

Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction.

JAMA Cardiol 2021 May 5. Epub 2021 May 5.

University of Utah School of Medicine, Salt Lake City.

Importance: Heart failure with recovered ejection fraction (HFrecEF) is a recently recognized phenotype of patients with a history of reduced left ventricular ejection fraction (LVEF) that has subsequently normalized. It is unknown whether such LVEF improvement is associated with improvements in health status.

Objective: To examine changes in health-related quality of life in patients with heart failure with reduced ejection fraction (HFrEF) whose LVEF normalized, compared with those whose LVEF remains reduced and those with HF with preserved EF (HFpEF). Read More

View Article and Full-Text PDF

Congestive Heart Failure-associated Chronic Diffuse Alveolar Hemorrhage.

Am J Respir Crit Care Med 2021 Apr 21. Epub 2021 Apr 21.

Koseiren Takaoka Hospital, 13869, Respiratory Medicine, Takaoka, Japan.

View Article and Full-Text PDF

Heart-lung interactions in COVID-19: prognostic impact and usefulness of bedside echocardiography for monitoring of the right ventricle involvement.

Authors:
Michael Dandel

Heart Fail Rev 2021 Apr 17. Epub 2021 Apr 17.

German Centre for Heart and Circulatory Research (DZHK) Partner Site, Berlin, Berlin, Germany.

Due to the SARS-CoV-2 infection-related severe pulmonary tissue damages associated with a relative specific widespread thrombotic microangiopathy, the pathophysiologic role of heart-lung interactions becomes crucial for the development and progression of right ventricular (RV) dysfunction. The high resistance in the pulmonary circulation, as a result of small vessel thrombosis and hypoxemia, is the major cause of right heart failure associated with a particularly high mortality in severe COVID-19. Timely identification of patients at high risk for RV failure, optimization of mechanical ventilation to limit its adverse effects on RV preload and afterload, avoidance of medication-related increase in the pulmonary vascular resistance, and the use of extracorporeal membrane oxygenation in refractory respiratory failure with hemodynamic instability, before RV failure develops, can improve patient survival. Read More

View Article and Full-Text PDF

A Heart Failure-Associated Splice Variant Leads to a Reduction in Sodium Current Through Coupled-Gating With the Wild-Type Channel.

Front Physiol 2021 22;12:661429. Epub 2021 Mar 22.

Department of Physiology and Cell Biology, Frick Center for Heart Failure and Arrhythmias, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States.

Na1.5, encoded by the gene , is the predominant voltage-gated sodium channel expressed in the heart. It initiates the cardiac action potential and thus is crucial for normal heart rhythm and function. Read More

View Article and Full-Text PDF

Emergent surgery for cardiac herniation coexisting with complex blunt cardiac injury: A case report.

Trauma Case Rep 2021 Apr 17;32:100464. Epub 2021 Mar 17.

Shock & Trauma Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai-city, Chiba 270-1694, Japan.

A 38-year-old man was pressed on his trunk by a heavy object weighing about 100 kg. The patient was in shock status on arrival to the hospital. Circular collapse progressed rapidly during contrast computed tomography (CT) scanning. Read More

View Article and Full-Text PDF

Mitral valve replacement through mini sternotomy after long ECMO course: Case report.

Perfusion 2021 Mar 29:2676591211003237. Epub 2021 Mar 29.

Department of Cardiothoracic Surgery, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Introduction: Mitral regurgitation (MR) is defined as an abnormal reversal of blood flow from the left ventricle to the left atrium (LA). It is caused by disruption in any part of the mitral valve apparatus. Surgical intervention remains the mainstay of management for severe cases. Read More

View Article and Full-Text PDF

Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.

Lancet 2021 Mar;397(10280):1195-1203

UMRS 1169 VIMA, INSERM, Versailles Saint-Quentin University, Versailles, France.

Background: Shortening the duration of antibiotic therapy for patients admitted to hospital with community-acquired pneumonia should help reduce antibiotic consumption and thus bacterial resistance, adverse events, and related costs. We aimed to assess the need for an additional 5-day course of β-lactam therapy among patients with community-acquired pneumonia who were stable after 3 days of treatment.

Methods: We did this double-blind, randomised, placebo-controlled, non-inferiority trial (the Pneumonia Short Treatment [PTC]) in 16 centres in France. Read More

View Article and Full-Text PDF

Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients.

Front Immunol 2021;12:648004. Epub 2021 Mar 9.

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Deficient interferon responses have been proposed as one of the relevant mechanisms prompting severe manifestations of COVID-19. To evaluate the interferon (IFN)-α levels in a cohort of COVID-19 patients in relation to severity, evolution of the clinical manifestations and immune/inflammatory profile. This is prospective study recruiting consecutive hospitalized patients with respiratory failure associated with SARS-COV-2 infection and matched controls. Read More

View Article and Full-Text PDF

Staged Endovascular Repair of Aortic Coarctation followed by Double Valve Surgery.

Aorta (Stamford) 2020 Dec 24;8(6):178-180. Epub 2021 Mar 24.

Department of Surgery, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

We present a unique case of late diagnosis of coarctation of the aorta in an adult, presenting with congestive heart failure associated with severe aortic and mitral valve insufficiency. To minimize operative risk, staged endovascular repair of the coarctation was initially performed, followed by aortic valve replacement and mitral valve repair. Six months postoperatively, the 41-year-old patient remains completely asymptomatic. Read More

View Article and Full-Text PDF
December 2020

A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure.

Cardiol Res 2021 Apr 23;12(2):60-66. Epub 2021 Feb 23.

Saba University School of Medicine, Church Street, The Bottom, Saba, Dutch Caribbean. Email:

Diabetes mellitus is a well-known risk factor for heart failure, and the reasons why are well understood. The incidence of diabetes mellitus is continuing to rise, posing a major concern in the medical world. The comorbidities associated with diabetes mellitus create a major hindrance on daily living, and promote the development of a plethora of other diseases. Read More

View Article and Full-Text PDF

Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells.

Leukemia 2021 Mar 17. Epub 2021 Mar 17.

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Pediatric myelodysplastic syndromes (MDS) are a heterogeneous disease group associated with impaired hematopoiesis, bone marrow hypocellularity, and frequently have deletions involving chromosome 7 (monosomy 7). We and others recently identified heterozygous germline mutations in SAMD9 and SAMD9L in children with monosomy 7 and MDS. We previously demonstrated an antiproliferative effect of these gene products in non-hematopoietic cells, which was exacerbated by their patient-associated mutations. Read More

View Article and Full-Text PDF

Delayed-onset constrictive pericarditis associated with trauma.

BMJ Case Rep 2021 Mar 16;14(3). Epub 2021 Mar 16.

Department of Cardiology, Japan Community Healthcare Organization (JCHO) Osaka Hospital, Osaka, Japan.

A 59-year-old man presented with exertional dyspnoea and pretibial oedema that had lasted 6 months. He was referred to our hospital with suspected constrictive pericarditis (CP). Several examinations, including CT, echocardiography and cardiac catheterisation, indicated heart failure associated with CP that had been induced by trauma 13 years prior. Read More

View Article and Full-Text PDF

Effusion-Serum Chloride Gradient in Heart Failure-Associated Pleural Effusion - Pathophysiologic Implications.

Authors:
Hajime Kataoka

Circ Rep 2020 Jun 2;2(7):357-363. Epub 2020 Jun 2.

Internal Medicine, Nishida Hospital Oita Japan.

There is scant clinical data of electrolyte analyses in the pleural fluid under heart failure (HF) pathophysiology. This study retrospectively analyzed data from 17 consecutive patients who presented with pleural effusion and underwent thoracentesis. A diagnosis of worsening HF was established by clinical criteria (presentation, echocardiography, serum B-type natriuretic peptide, and response to therapy). Read More

View Article and Full-Text PDF

The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis.

Front Pharmacol 2021 18;12:628184. Epub 2021 Feb 18.

Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

Substantial controversies exist in the exploration of the molecular mechanism of heart failure (HF) and pose challenges to the diagnosis of HF and the discovery of specific drugs for the treatment. Recently, cardiac transthyretin (TTR) amyloidosis is becoming recognized as one of major causes of underdiagnosed HF. The investigation and modulation of TTR misfolding and amyloidal aggregation open up a new revenue to reveal the molecular mechanisms of HF and provide new possibilities for the treatment of HF. Read More

View Article and Full-Text PDF
February 2021

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction.

Korean Circ J 2021 Mar;51(3):251-262

Department of Convergence Medicine, Pusan National University School of Medicine, Yangsan, Korea.

Background And Objectives: Large clinical studies of sodium/glucose cotransporter 2 (SGLT2) inhibitors have shown a significant beneficial effect on heart failure-associated hospitalization and cardiovascular events. As SGLT2 is known to be absent in heart cells, improved cardiovascular outcomes are thought to be accounted for by the indirect effects of the drug. We sought to confirm whether such benefits were mediated through SGLT2 expressed in the heart using myocardial infarction (MI) model. Read More

View Article and Full-Text PDF

[Trisomy 18 or postnatal Edward´s syndrome: descriptive study conducted at the University Hospital Center of Casablanca and literature review].

Pan Afr Med J 2020 3;37:309. Epub 2020 Dec 3.

Laboratoire de Génétique Médicale, Centre Hospitalier Universitaire Ibn Rochd de Casablanca, Casablanca, Maroc.

Trisomy 18 is a chromosomal disease, caused by the presence of a supernumerary chromosome 18. Mortality among infants with trisomy 18 is high, secondary to lethal malformations associated with this syndrome. The purpose of this study was to describe the clinical and cytogenetic features of these patients, as well as the role of genetic counselling. Read More

View Article and Full-Text PDF

Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.

J Urol 2021 May 24;205(5):1430-1437. Epub 2021 Feb 24.

Department of Urology, Queen's University, Kingston, Ontario, Canada.

Purpose: Increased risk of cardiac failure with α-blockers in hypertension studies and 5-alpha reductase inhibitors in prostate studies have raised safety concerns for long term management of benign prostatic hyperplasia. The objective of this study was to determine if these medications are associated with an increased risk of cardiac failure in routine care.

Materials And Methods: This population based study used administrative databases including all men over 66 with a diagnosis of benign prostatic hyperplasia between 2005 and 2015. Read More

View Article and Full-Text PDF

High Output Heart Failure Associated With Arteriovenous Fistula in the Setting of Kidney Transplantation.

Kidney Int Rep 2021 Feb 10;6(2):544-551. Epub 2020 Nov 10.

Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

View Article and Full-Text PDF
February 2021

Frailty of the Heart Recipient.

Authors:
Peter Macdonald

Transplantation 2021 Feb 11. Epub 2021 Feb 11.

Medical Director, Heart Transplant Unit, St Vincent's Hospital Head, Transplantation Research Laboratory, Victor Chang Cardiac Research Institute Professor of Medicine, University of New South Wales.

Frailty has been defined as a state of increased vulnerability due to a decline in the reserve and function of multiple physiological systems. Initially conceived as a geriatric syndrome indicative of physiological aging, it is now apparent that frailty can also be observed as a manifestation of chronic disease states including heart failure. Estimates of the prevalence of frailty in heart failure vary according to the age of the study population and the frailty instrument used, however multiple studies have identified frailty to be prevalent in patients with advanced heart failure including those who are referred for heart transplantation. Read More

View Article and Full-Text PDF
February 2021

Translational Sciences in Cardiac Failure Secondary to Arteriovenous Fistula in Hemodialysis Patients.

Ann Vasc Surg 2021 Feb 6. Epub 2021 Feb 6.

Vascular & Endovascular Surgery, Royal Blackburn Teaching Hospital, Blackburn, UK. Electronic address:

High-output cardiac failure is a rare form of heart failure associated with the formation of arteriovenous fistula (AVF) in hemodialysis patients. The pathophysiology underlying the HOCF is complex and multifactorial. Presence of AVF can cause long term hemodynamic changes that ultimately lead to increased cardiac output and consequently cardiac failure. Read More

View Article and Full-Text PDF
February 2021

Real-world experience of suture-based closure devices: Insights from the FDA Manufacturer and User Facility Device Experience.

Catheter Cardiovasc Interv 2021 Feb 4. Epub 2021 Feb 4.

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Objectives: We analyzed post-marketing surveillance data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database for suture-based vascular closure devices (VCDs) - Perclose ProGlide (Abbott, Chicago, Illinois) and Prostar XL (Abbott).

Background: Suture-based VCDs are mostly used for large-bore femoral arterial access-site closure. Real-world, contemporary experience on the most commonly reported complications and modes of failure associated with these devices is limited. Read More

View Article and Full-Text PDF
February 2021

Real-World Experience of the MANTA Closure Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database.

Cardiovasc Revasc Med 2021 Jun 20;27:63-66. Epub 2020 Nov 20.

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America. Electronic address:

Background/purpose: The MANTA vascular closure device (VCD) is the first commercially available dedicated closure device for large-bore femoral arterial access-site closure and was approved by the United States Food and Drug Administration (FDA) in February 2019. Real-world data on the most commonly reported complications and modes of failure associated with the MANTA closure device are limited. We analyzed post-marketing surveillance data from FDA's Manufacturer and User Facility Device Experience (MAUDE) database for the MANTA VCD (Teleflex, Wayne, Pennsylvania). Read More

View Article and Full-Text PDF

Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation.

PLoS Biol 2020 12 28;18(12):e3000739. Epub 2020 Dec 28.

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Cardiac levels of the signal transducer and activator of transcription factor-3 (STAT3) decline with age, and male but not female mice with a cardiomyocyte-specific STAT3 deficiency conditional knockout (CKO) display premature age-related heart failure associated with reduced cardiac capillary density. In the present study, isolated male and female CKO-cardiomyocytes exhibit increased prostaglandin (PG)-generating cyclooxygenase-2 (COX-2) expression. The PG-degrading hydroxyprostaglandin-dehydrogenase-15 (HPGD) expression is only reduced in male cardiomyocytes, which is associated with increased prostaglandin D2 (PGD2) secretion from isolated male but not female CKO-cardiomyocytes. Read More

View Article and Full-Text PDF
December 2020

Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan.

Kidney Med 2020 Nov-Dec;2(6):742-752.e1. Epub 2020 Oct 17.

Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka, Japan.

Rationale & Objective: Hyperkalemia is a common electrolyte abnormality of chronic kidney disease and heart failure associated with increased mortality and morbidity. We aimed to assess the long-term economic burden of hyperkalemia.

Design: Observational cohort study using a Japanese nationwide hospital claims database (April 1, 2008, to September 30, 2018). Read More

View Article and Full-Text PDF
October 2020